ΔΕΛΤΙΟ ΤΥΠΟΥ ΔΕΛΤΙΟ ΤΥΠΟΥ ΔΕΛΤΙΟ ΤΥΠΟΥ

Key Financial Figures for the Nine-Month Period 2025

11.2% increase in Adjusted EBITDA
from continuing and discontinued operations

Peania, November 17, 2025 – Lavipharm S.A. informs the investment community of the Group's key consolidated financial figures for the nine-month period of 2025.

Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) from continuing and discontinued operations increased by 11.2%, reaching €10.47 million compared to €9.42 million in the corresponding period of the previous year. Adjusted EBITDA from continuing operations amounted to €9.52 million versus €9.28 million in the same period last year, marking a 2.7% increase.

It should be noted that expenses were impacted by €0.71 million, representing a non-cash accounting related to the valuation of the Company's stock award and stock option plans corresponding to the period.

Consolidated sales before clawback and rebates amounted to €47.74 million, compared to €45.54 million in the same period last year, representing an increase of 4.8%.

Gross profit for the nine-month period of 2025 stood at €18.81 million, compared to €19.52 million in the same period of 2024, reflecting a slight decrease of 3.6%.

Net profit after taxes amounted to €3.51 million, compared to €9.22 million in the nine-month period of 2024, reflecting a decline due to the fact that last year's results benefited from the extraordinary recognition of a deferred tax asset, arising from the Group's decision to liquidate subsidiary companies that had previously accumulated significant tax losses.

As of September 30, 2025, net debt stood at €29.78 million.

Regarding sales performance, the export sector recorded a temporary decrease of 27.5%. In the domestic market, prescription drug sales increased by 37.7%, while OTC products rose by 4%. Other sales, representing 0.2% of total turnover and relating to secondary activities, declined by 75.8%, as a result of a strategic decision by the Group.

Outlook for Q4 2025

The decline in exports during the first nine months of 2025 is considered temporary. Export activity depends on customer orders according to their own sales and inventory planning. Based on the current order book, the downward trend in exports is expected to fully reverse in the fourth quarter, with sales projected to reach approximately €10.5 million, compared to €13.7 million during the first nine months of 2025.

As for domestic prescription drug sales, an accelerated growth rate is anticipated in the final quarter of the year, driven primarily by the increase in medical cannabis sales, which were exceptionally low during the same period of 2024. The export timing in the final quarter of the year, along with the continued strong growth of domestic prescription drug sales, is expected to drive a substantial increase in adjusted EBITDA, both in comparison with the same period last year and relative to the first nine months of 2025.

KEY CONSOLIDATED FINANCIAL FIGURES

(values in million Euro)	9month 2025	9 month 2024	Movement (%)
Total Sales before Clawback-Rebates	**47,74**	**45,54**	**4,8%**
Rebate & Clawback	**6,13**	**6,09**	**0,7%**
Net Sales	**41,61**	**39,45**	**5,5%**
Gross Profit	**18,81**	**19,52**	**-3,6%**
Adjusted Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) from continuing operations *	**9,52**	**9,28**	**2,7%**
Adjusted Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) from continuing & discontinued operations	**10,47**	**9,42**	**11,2%**
Earnings before Tax from continuing operations	**4,33**	**4,55**	**-4,9%**
Earnings after Tax from continuing operations	**2,57**	**9,17**	**-71,9%**
Earnings before Tax from continuing & discontinued operations	**3,51**	**9,22**	**-61,9%**

GROUP SALES ANALYSIS BY CATEGORY

(values in million Euro)	9month 2025	9 month 2024	Movement (%)
Prescription pharmaceuticals domestic sales	27,19	19,75	37,7%
OTC Sales	6,80	6,54	4,0%
Pharmaceuticals exports	13,66	18,83	-27,5%
Other sales	0,10	0,43	-75,8%
Total Sales	**47,74**	**45,54**	**4,8%**

For further information:

Investor Relations
Vassilis Baloumis
Tel.: +30 210 6691 121
ir@lavipharm.com

Corporate Communications
Vivien Thomas
Tel.: +30 210 6691 404
vthomas@lavipharm.com